Michael Ciarametaro, MBA

In the health spending debate, what policy makers need most is an honest, realistic, and evidence-based discussion. Unfortunately, many studies in the public arena fall far short.

Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.

Transformative therapies with high up-front costs will exacerbate the need to address gaps between payers when costs and benefits occur at different times.